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Abstract
Background: To evaluate computer-based computer tomography (CT) analysis (CALIPER) against visual CT scoring
and pulmonary function tests (PFTs) when predicting mortality in patients with connective tissue disease-related
interstitial lung disease (CTD-ILD). To identify outcome differences between distinct CTD-ILD groups derived
following automated stratification of CALIPER variables.
Methods: A total of 203 consecutive patients with assorted CTD-ILDs had CT parenchymal patterns evaluated by
CALIPER and visual CT scoring: honeycombing, reticular pattern, ground glass opacities, pulmonary vessel volume,
emphysema, and traction bronchiectasis. CT scores were evaluated against pulmonary function tests: forced vital
capacity, diffusing capacity for carbon monoxide, carbon monoxide transfer coefficient, and composite physiologic
index for mortality analysis. Automated stratification of CALIPER-CT variables was evaluated in place of and
alongside forced vital capacity and diffusing capacity for carbon monoxide in the ILD gender, age physiology
(ILD-GAP) model using receiver operating characteristic curve analysis.
Results: Cox regression analyses identified four independent predictors of mortality: patient age (P < 0.0001), smoking
history (P = 0.0003), carbon monoxide transfer coefficient (P = 0.003), and pulmonary vessel volume (P < 0.0001).
Automated stratification of CALIPER variables identified three morphologically distinct groups which were stronger
predictors of mortality than all CT and functional indices. The Stratified-CT model substituted automated stratified
groups for functional indices in the ILD-GAP model and maintained model strength (area under curve (AUC) = 0.74,
P < 0.0001), ILD-GAP (AUC = 0.72, P < 0.0001). Combining automated stratified groups with the ILD-GAP model
(stratified CT-GAP model) strengthened predictions of 1- and 2-year mortality: ILD-GAP (AUC = 0.87 and 0.86,
respectively); stratified CT-GAP (AUC = 0.89 and 0.88, respectively).
Conclusions: CALIPER-derived pulmonary vessel volume is an independent predictor of mortality across all CTD-ILD
patients. Furthermore, automated stratification of CALIPER CT variables represents a novel method of prognostication
at least as robust as PFTs in CTD-ILD patients.
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Background
Computed tomography (CT) evaluation of patients with
individual connective tissue disease-related interstitial
lung diseases (CTD-ILDs) have shown that several
parenchymal patterns, including honeycombing [1, 2],
reticulation [3], and fibrosis extent, are associated with
a poor outcome [1, 4–6]. However, while studies of
prognostic indices within individual CTDs convey valu-
able information about specific, small patient groups,
the applicability of such indices to a wider group of
“all-comers” CTDs needs validation.
The importance of identifying prognostic indices across
a population of various CTD diagnoses lies in the fact that
CTD sub-groups often overlap both in their clinical and
CT characteristics. Yet, there are very few CT studies that
have considered mixed populations of CTD patients. One
such study, by Walsh et al. [7], identified severity of
traction bronchiectasis and honeycombing as indices
predictive of mortality, confirming the importance of
two parenchymal patterns previously shown to be prog-
nostically important in the non-CTD idiopathic inter-
stitial pneumonias [8–10].
Computer-based CT analysis in the CTDs [11, 12] has
been relatively neglected when compared to idiopathic
pulmonary fibrosis (IPF) [13–15]. Furthermore, the
application of advanced mathematical modelling tech-
niques to CT datasets has been limited thus far [16]
despite the modelling of quantified CT variables having
the potential to provide a comprehensive morphological
analysis of a patient’s disease. By evaluating the entirety
of a CT dataset, computer tools, when allied to model-
ling techniques, can identify patient clusters that share
similar disease phenotypes and potentially identify sub-
groups with similar outcomes.
The current study therefore compared the strength of
visual and computer-based (CALIPER) CT patterns and
pulmonary function tests (PFTs) for the prediction of
mortality for a mixed cohort of CTD-ILD patients. A
secondary analysis evaluated mortality prediction across
the entire cohort using mathematical modelling of
CALIPER-scored CT variables and compared mortality
prediction against the interstitial lung disease gender,
age physiology (ILD-GAP) outcome model.
Methods
Study cohort
A retrospective analysis of an ILD database identified all
new consecutive patients with a multidisciplinary diag-
nosis of CTD-ILD, diagnosed according to published
guidelines [17] over a 4.5-year period (January 2007 to
July 2011). Underlying CTD diagnoses were defined
according to the relevant rheumatology diagnostic
guidelines [18–24]. Patients with a non-contrast, su-
pine, volumetric thin section CT were captured, and
subsequent exclusions are shown as per the CONSORT
diagram in Additional file 1: Figure S1. Approval for
this analysis of clinically indicated CT and pulmonary
function data was obtained (and patient consent was
waived) from the Institutional Ethics Committee of the
Royal Brompton Hospital and the Institutional Review
Board of the Mayo Clinic.
Study protocols
CT, CALIPER and PFT protocols have been previously
described [25]. PFTs analysed included forced expiratory
volume in one second (FEV1), forced vital capacity
(FVC), total lung capacity (TLC), transfer coefficient of
the lung for carbon monoxide (Kco), single breath carbon
monoxide diffusing capacity corrected for haemoglobin
concentration (DLco), and the composite physiologic
index (CPI) [26].
CT evaluation
Each CT scan was evaluated independently by two radi-
ologists (AB, RE) with 7 and 9 years thoracic imaging
experience, respectively, blinded to all clinical informa-
tion [25]. Visual CT parameters included ground glass
opacity, reticular pattern, honeycombing, emphysema,
consolidation, mosaicism (decreased attenuation com-
ponent), and traction bronchiectasis as described in
Additional file 1: Appendix. CALIPER evaluation of the
lungs [13] is described in Additional file 1: Appendix
and was pictorially expressed as a glyph [27] (Fig. 1).
Total fibrosis extent represented the sum of reticulation
and honeycombing, whilst total ILD extent additionally
summed ground glass opacification. All CT variables were
expressed as a percentage, to the nearest 5%, of the total
lung volume except traction bronchiectasis which was
scored using a categorical 4-point lobar scale [25].
Stratification of CALIPER-derived parenchymal pattern
extents
Within each of three lung zones (upper, middle and
lower), CALIPER evaluated parenchymal pattern extents
in both the medial and lateral regions of a zone [13].
Within the resulting 12 zones, global and regional dis-
similarities in the eight CALIPER-quantified patterns
(ground glass opacity, reticular pattern, honeycombing,
grade 1 low attenuation areas (LAA), grade 2 LAA,
grade 3 LAA, and normal lung and pulmonary vessel
volume (PVV)) were evaluated by a dissimilarity metric
[16]. The dissimilarity metric evaluated regional dissimi-
larities in lung volume separately within each lung as a
proportion of the total lung volume. Between two individ-
ual lungs, dissimilarities in the proportions of absolute
lung volumes in corresponding regions as well as dissimi-
larities in the proportions of specific parenchymal patterns
in the corresponding regions were also calculated.
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Fig. 1 (See legend on next page.)
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The dissimilarity metric was used to compare all 203
CTD-ILD cases in a pairwise manner. The resultant
203 × 203 matrix was stratified using single pass un-
supervised affinity propagation [28] to identify unique
clusters that represented patient groups with common
parenchymal features. No pre-test designation as to the
number of expected clusters was necessary, as affinity
propagation derives naturally occurring clusters using
real-valued message exchange [28].
Statistical analysis
Data are given as means with standard deviations, or
numbers of patients with percentages where appropriate.
Interobserver variation for visual scores was assessed
using the single determination standard deviation. Linear
and logistic regression analyses were used to examine re-
lationships between PVV and CT, echocardiographic and
functional variables. Univariate and multivariate Cox
proportional hazards analyses were used to investigate
relationships within and between the three data sets:
CALIPER CT evaluation, visual CT evaluation and PFTs.
Variables were removed from multivariate models in a
stepwise manner at a 0.01 level of significance.
Differences in functional and morphological indices
between groups created following automated stratifica-
tion of CALIPER parenchymal pattern scores were ex-
amined using one-way analysis of variance (ANOVA)
and post-ANOVA pairwise t-test analyses with the
Bonferroni correction applied for multiple analyses.
Cox regression analysis and Kaplan–Meier survival
curves compared using the Log rank test were used to
identify survival differences between automated strati-
fied groups.
Analyses using patient outcome models
The ILD-GAP model, a staging system determining
patient outcome, was evaluated in the current study
against the automated stratified CTD-ILD groups. The
ILD-GAP model categorically weighs four variables
(age, gender, FVC and DLco) and generates a 4-point
categorical scale from an 8-point score [29].
In the primary analysis between outcome models, the
ability of automated stratified CALIPER-CT groups to
substitute for the pulmonary function variables (FVC
and DLco) in the ILD-GAP model was investigated.
The automated stratified groups were converted into a
5-point categorical scale in line with the 5-point
weighting of FVC and DLco in the ILD-GAP score,
from which the ILD-GAP model is derived. Stratified
group 1 patients were assigned a score of 0, stratified
group 2 patients a score of 2, and stratified group 3 pa-
tients a score of 4. Gender and age were scored on 2-
and 3-point scales in accordance with the ILD-GAP
score and were combined with the stratified group
scores to create an 8-point scale (“Stratified-CT score”).
The reason for the 5-point weighting of the automated
stratified groups was to maintain the weighting of age
and gender in the Stratified-CT score when compared
to the ILD-GAP model, where the weighting of FVC
(0,1,2) and DLco (0,1,2) was spread across a 5-point
scale. Had a 3-point scale been used for the automated
stratified groups, in the subsequently created models,
patient age and gender would have been as powerful in
determining outcome as the CT variables (stratified
groups), which would have biased our results when
comparisons to the ILD-GAP index were evaluated.
The 8-point Stratified-CT score was condensed into a 4-
point model in line with the ILD-GAP model and was
termed the “Stratified-CT model”, where a score of 0/1
represented grade 1, a score of 2/3 represented grade 2, a
score of 4/5 represented grade 3, and a score over 5 repre-
sented grade 4. Finally, the automated stratified groups
(measured on a 3-point scale) were combined with the
ILD-GAP model (which amalgamated patient age, gender,
FVC and DLco in an 8-point ILD-GAP score as previously
described and was then converted into a 4-point ILD-
GAP model) to form a “Stratified CT-GAP model”.
The predictive power of the Stratified CT model, the
ILD-GAP model and the Stratified CT-GAP model to
determine mortality in the same 179 patients was evalu-
ated using univariate and multivariate Cox mortality
analyses with bootstrapping of 1000 randomly generated
samples as well as receiver operator characteristic (ROC)
curve analysis. Statistical analyses were performed with
IBM SPSS Statistics for Macintosh, Version 20.0.
Armonk, NY: IBM Corp.
(See figure on previous page.)
Fig. 1 a–c Glyphs demonstrating the CT parenchymal pattern extents of each patient in each of the three connective tissue disease-related
interstitial lung disease groups (a = Group 1 (n = 15); b = group 2 (n = 138); c = group 3 (n = 50)) derived following CALIPER CT analysis. Each
glyph comprises six wedges, corresponding to lung zones (upper, middle and lower for each lung). The size of a wedge reflected the volume
of the zone relative to the total lung volume. Within each lung zone, every voxel was classified into one of eight separately colour coded
CALIPER parenchymal patterns: ground glass opacity, yellow; reticular pattern, orange; honeycombing, brown; Grade 1 decreased attenuation
(DA), light green; Grade 2 DA, light blue; Grade 3 DA, dark blue; Normal lung, dark green; pulmonary vessel volume (PVV; pulmonary arteries
and veins, excluding vessels at the lung hilum), white. The relative volumes of the patterns within a zone determined the proportions of each
colour in a zone; dotted concentric lines represent quintiles of lung volume
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Results
Cohort analysis
A total of 203 patients were identified with the following
CTD diagnoses: rheumatoid arthritis (RA, n = 50), systemic
sclerosis (n = 65), overlap CTD (n = 36, polymyositis and
dermatomyositis (n = 23), mixed connective tissue disease
(n = 16), primary Sjögren’s syndrome (n = 10), and systemic
lupus erythematosus (SLE, n = 3); 69% of the CTD cohort
were female, 60% had never smoked, and 65% were still
alive after a mean follow-up time of 46 months.
Baseline CT analysis
Visual scoring generally identified more extensive ILD
and emphysema than CALIPER across all groups (Table 1).
ILD was mainly comprised of ground glass opacity on
CALIPER but consisted of slightly more extensive
reticular pattern than ground glass opacity on visual
scoring. Interobserver agreement between the visual
scorers is provided in Additional file 1: Table S2. Differ-
ences in disease extents between ILD-GAP groups are
shown in Additional file 1: Table S3.
Table 1 Patient age, gender, smoking status and measures of pulmonary function indices, CALIPER and visually scored CT parameters
and echocardiography data in patients with connective tissue disease-related interstitial lung disease with a subanalysis for each of three
separate groups derived following mathematical modelling using automated stratification
Variable All CTD Stratified Group 1 Stratified Group 2 Stratified Group 3
Units are percentage unless stated (n = 203 unless stated) (n = 15 unless stated) (n = 138 unless stated) (n = 50 unless stated)
Median age, years 58 58 59 53
Male/female 63/140 2/13 47/91 14/36
Survival (alive/dead) 131/72 14/1 95/43 22/28
Never/ex-smokers 122/76 9/6 83/52 30/18
Follow-up time, months 45.9 ± 24.0 57.8 ± 15.3 47.4 ± 22.2 38.1 ± 28.5
FEV1 % predicted 68.7 ± 18.4 (184) 79.5 ± 14.7 (14) 71.4 ± 18.3 (122) 58.7 ± 15.4 (48)
FVC % predicted 70.8 ± 20.9 (184) 88.3 ± 15.6 (14) 74.4 ± 20.7 (122) 56.7 ± 13.9 (48)
DLco % predicted 39.3 ± 14.2 (189) 54.5 ± 14.4 (14) 41.6 ± 13.0 (129) 28.4 ± 9.8 (46)
Kco % predicted 66.1 ± 17.6 (189) 72.2 ± 17.4 (14) 68.0 ± 16.8 (129) 58.9 ± 18.0 (46)
TLC % predicted 70.9 ± 16.7 (175) 89.6 ± 13.6 (13) 72.7 ± 16.0 (121) 59.4 ± 11.2 (41)
CPI 51.2 ± 13.7 (180) 35.8 ± 11.9 (14) 48.6 ± 12.6 (120) 62.7 ± 8.0 (46)
CALIPER ILD extent 20.2 ± 18.3 2.4 ± 2.1 12.7 ± 8.7 46.2 ± 15.0
CALIPER Fibrosis extent 5.5 ± 5.2 0.7 ± 0.5 4.0 ± 3.4 11.0 ± 5.9
CALIPER GGO 14.7 ± 15.7 1.7 ± 1.9 8.7 ± 7.8 35.2 ± 16.3
CALIPER Reticular pattern 4.9 ± 4.6 0.6 ± 0.4 3.7 ± 3.0 9.8 ± 5.3
CALIPER Honeycombing 0.6 ± 1.5 0.1 ± 0.1 0.4 ± 0.7 1.2 ± 2.8
CALIPER Emphysema 0.6 ± 2.8 0.1 ± 0.1 0.9 ± 3.3 0.2 ± 0.7
CALIPER PVV 4.2 ± 1.7 2.5 ± 0.5 3.6 ± 1.1 6.5 ± 1.3
CALIPER Normal lung 74.9 ± 19.5 95.1 ± 2.3 82.8 ± 9.5 47.1 ± 15.2
Visual ILD extent 53.5 ± 24.8 43.1 ± 28.4 47.4 ± 23.0 73.5 ± 17.0
Visual fibrosis extent 31.7 ± 19.9 7.2 ± 6.9 27.6 ± 16.4 50.6 ± 16.7
Visual GGO 20.7 ± 20.0 34.1 ± 28.8 18.9 ± 19.1 21.7 ± 17.9
Visual reticular pattern 27.6 ± 17.9 7.2 ± 6.9 24.9 ± 15.4 41.1 ± 17.7
Visual honeycombing 4.1 ± 9.3 0.0 ± 0.0 2.7 ± 6.6 9.4 ± 14.1
Visual consolidation 0.6 ± 2.3 1.8 ± 4.9 0.6 ± 2.2 0.4 ± 1.0
Visual emphysema 4.1 ± 10.7 5.0 ± 16.9 3.8 ± 9.8 4.8 ± 10.9
Visual mosaicism 1.7 ± 4.9 3.9 ± 8.1 1.4 ± 4.9 1.9 ± 3.6
Visual TxBx (max score 18) 5.5 ± 3.7 1.0 ± 1.2 5.1 ± 3.4 7.9 ± 3.6
Main PA diameter, mm 31.0 ± 4.8 28.7 ± 4.0 30.4 ± 4.3 33.3 ± 5.6
AAo diameter, mm 32.0 ± 4.0 31.9 ± 3.3 31.8 ± 4.0 32.7 ± 4.0
RVSP, mmHg 39.2 ± 16.1 (100) 28.9 ± 3.8 (7) 37.0 ± 14.7 (62) 45.8 ± 18.1 (31)
Data represent mean values with standard deviations. CTD connective tissue disease, FEV1 forced expiratory volume in one second, FVC forced vital capacity, DLco
diffusing capacity for carbon monoxide, Kco carbon monoxide transfer coefficient, TLC total lung capacity, CPI composite physiologic index, ILD interstitial lung disease,
GGO ground glass opacity, PVV pulmonary vessel volume, TxBx traction bronchiectasis, PA pulmonary artery, AAo ascending aorta, RVSP right ventricular systolic pressure
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To further evaluate the PVV variable, relationships with
markers of interstitial disease and pulmonary vascular
disease were explored. On linear regression analyses, PVV
demonstrated strong linkages with CALIPER ILD extent
(R2 = 0.73, P < 0.0001) and visual ILD extent (R2 = 0.39,
P < 0.0001) but only weak associations with RVSP (R2 =
0.09, P = 0.002) and Kco (R2 = 0.05, P = 0.002).
Mortality analysis
On univariate mortality analysis, predictors of mortality
included CALIPER and visual measures of fibrosis
including reticular pattern, honeycombing, and ILD
and fibrosis extents as well as visual traction bronchi-
ectasis and CALIPER PVV (Table 2). Of the pulmon-
ary function indices, DLco, Kco, and the CPI were
strong univariate predictors of mortality (Table 2).
Patient age and a positive smoking history were also
strongly linked to mortality. Univariate mortality ana-
lyses were also performed for the continuous scores
(prior to their categorization into indices) of the three
models: ILD-GAP, Stratified CT, and Stratified CT-
GAP models (Table 2).
Table 2 Univariate Cox regression analysis of connective tissue disease-related interstitial lung disease (CTD-ILD) cases demonstrating
variables significantly predictive of mortality: CALIPER indices (top white), visually derived high-resolution computed tomography





P value 95% Confidence interval
Lower Upper
CALIPER score
Total ILD extent 203 1.02 0.002 1.01 1.03
Total fibrosis extent 203 1.12 <0.0001 1.08 1.16
Reticular pattern 203 1.12 <0.0001 1.08 1.16
Honeycombing 203 1.18 0.0004 1.08 1.29
Emphysema 203 1.08 0.004 1.02 1.13
Pulmonary vessel volume 203 1.37 <0.0001 1.19 1.57
VISUAL score
ILD extent 203 1.02 0.001 1.01 1.03
Fibrosis extent 203 1.03 <0.0001 1.02 1.04
Reticular pattern 203 1.02 0.002 1.01 1.03
Honeycombing 203 1.03 <0.0001 1.02 1.05
Traction bronchiectasis 203 1.16 <0.0001 1.09 1.24
Pulmonary artery diameter 203 1.09 0.0002 1.04 1.15
DLco 189 0.96 0.0004 0.94 0.98
Kco 189 0.97 0.0003 0.96 0.99
CPI 180 1.04 0.002 1.01 1.06
Age 203 1.06 <0.0001 1.04 1.09
Previous or current smoker 203 2.21 0.001 1.40 3.61
ECHOCARDIOGRAPHY RVSP 100 1.03 <0.0001 1.02 1.05
Continuous Model Score
ILD-GAP score 179 1.74 <0.0001 1.45 2.08
Stratified CT score 179 2.00 <0.0001 1.63 2.45
Stratified CT-GAP 179 1.65 <0.0001 1.41 1.94
MULTIVARIATE MODEL
Age 1.07 <0.0001 1.04 1.10
Previous/current smoker 2.87 0.0003 1.63 5.04
Pulmonary vessel volume 1.57 <0.0001 1.35 1.82
Kco 0.98 0.003 0.96 0.99
A multivariate model demonstrating independent predictors of mortality is also shown (bottom white).
ILD interstitial lung disease, FVC forced vital capacity, DLco diffusing capacity for carbon monoxide, Kco carbon monoxide transfer coefficient, CPI composite
physiologic index, RVSP right ventricular systolic pressure
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A combined multivariate analysis of the CTD cohort
included CALIPER and visual CT variables, pulmonary
function indices, and patient age and smoking history
(Table 2). DLco, Kco and CPI were each inserted into
the model as they demonstrated similar significance with
regard to mortality on univariate analysis. In the com-
bined model, patient age, smoking history, Kco and PVV
were the four variables independently predictive of mor-
tality (Table 2). In a separate multivariate Cox regression
analysis, no visual or CALIPER CT variable retained
significance against PVV after correction for age and
gender (at a significance level of 0.01). Of the pulmon-
ary functional indices, the only variable to maintain
significance against PVV for mortality prediction after
correction for age and gender was Kco. However, Kco
remained a weaker predictor of mortality than PVV
with identical P values to that shown in the multivariate
analysis in Table 2. PVV remained the strongest single
predictor of mortality in the CTD-ILD population.
Automated stratification of CTD-ILD patients
The CTD-ILD cohort was stratified into three outcome
groups using automated pairwise dissimilarity analyses.
The disease extents of the various CT parenchymal pat-
terns identified by CALIPER are pictorially represented
for the three outcome groups as glyphs in Fig. 1. Demo-
graphic, CT and functional characteristics of the three
groups are summarised in Table 1, whilst significant dif-
ferences in CT and functional variables between auto-
mated stratified groups are shown in Additional file 1:
Table S4.
Significant differences across all three groups were
identified for FVC, DLco, TLC and CPI, and all CALI-
PER measures of fibrosis except honeycombing. Simi-
larly, visual CT markers of fibrosis including fibrosis
extent, reticular pattern and traction bronchiectasis were
significantly different across all groups. CALIPER-
derived PVV was also significantly different across all
three groups.
Evaluation of automated stratified groups against mortality
Survival curves for the patients comprising the three
automated stratified groups are shown in Fig. 2a (Log
rank test P < 0.0001). Group 1 patients: n = 15; mean
survival = 77.4 ± 2.7 months), group 2: n = 138; mean
survival 66.4 ± 2.7 months, group 3: n = 50; mean sur-
vival 47.9 ± 5.2 months. The distribution of CTD-ILD
diagnoses between groups is given in Table 3. Group 3
patients had the worst outcome and included all CTD
diagnoses except SLE. Half of the patients with mixed
connective tissue disease and almost a third of patients
with RA, primary Sjögren’s syndrome, and polymyositis
and dermatomyositis were included in the poor out-
come group.
On univariate Cox regression analysis, the automated
stratified groups (n = 203) were strongly predictive of
mortality (hazard ratio (HR) = 2.45, confidence interval
(CI) 1.60–3.75, P < 0.0001). On bivariate mortality ana-
lyses, the automated stratified groups were stronger
determinants of outcome than any single CT or
pulmonary function index. In a bivariate mortality ana-
lysis with patient age, both variables were strongly inde-
pendently predictive of mortality (age: HR = 1.07, CI
1.04–1.09, P < 0.0001; and automated stratified groups:
HR = 2.98, CI 1.92–4.65, P < 0.0001).
Comparison of automated stratified groups against
patient outcome models
The ILD-GAP, Stratified CT, and Stratified CT-GAP
models were each highly predictive of mortality on uni-
variate analysis (Stratified CT: n = 203, HR = 3.18, CI
2.25–4.50, P < 0.0001; ILD-GAP: n = 179, HR = 2.89, CI
2.06–4.06, P < 0.0001; Stratified CT-GAP: n = 179, HR =
2.26, CI 1.76–2.91, P < 0.0001). Only 179 patients were
evaluated in the ILD-GAP and Stratified CT-GAP
models as 24 patients did not have FVC or DLco mea-
surements. When the same 24 patients were excluded
from the Stratified CT model, model strength improved
(Stratified CT: n = 179, HR = 3.77, CI 2.51–5.66, P <
0.0001). In subsequent analyses, only the 179 patients
common to the three models were compared.
When the Stratified CT and the ILD-GAP models
were evaluated using bivariate Cox mortality analysis,
the Stratified CT model was a stronger predictor of
mortality (Stratified CT: n = 179, HR = 2.49, CI 1.54–4.01,
P = 0.0002; ILD-GAP: n = 179, HR = 1.85, CI 1.24–2.76,
P = 0.003). The results were maintained on bootstrapping
of 1000 samples (Stratified CT: n = 179, P = 0.001, CI
0.41–1.52; ILD-GAP: n = 179, P = 0.003, CI 0.20–1.09).
Survival curves for the 179 CTD-ILD patients sepa-
rated according to the ILD-GAP model and the same
179 CTD-ILD patients separated according to the
Stratified CT model are demonstrated in Fig. 2b and c,
respectively. The relatively reduced HR demonstrated
for the Stratified-GAP model was a consequence of its
wider 7-point scale, but the narrow confidence interval
range highlights its strength over the other models.
On ROC curve analysis, prediction of mortality at
1 year, 2 years and overall mortality was analysed for the
three models: ILD-GAP model, Stratified CT model, and
the Stratified CT-GAP model (Fig. 3); 18/179 patients
died within a year of the CT scan being performed,
whilst 30/179 patients died within 2 years. The area
under the ROC curve (AUROCC) was consistently
higher for the Stratified CT-GAP model when compared
to the ILD-GAP model, and was higher for 1-year and
overall mortality with the Stratified CT model over the
ILD-GAP model.
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Fig. 2 (See legend on next page.)
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Discussion
Our study has demonstrated for the first time, that,
across the range of CTD-ILD diagnoses, a computer-
derived CT parameter, the pulmonary vessel volume, is
an independent predictor of mortality. Furthermore, the
PVV is a stronger predictor of mortality than all other
CT and pulmonary function variables following correc-
tion for age and gender. In addition, automated stratifi-
cation of CALIPER-derived CT variables identifies
patient groups with distinct characteristics, and three
automated stratified groups demonstrated significantly
different functional profiles and patient outcomes. When
the functional indices (FVC, DLco) in the ILD-GAP
model were substituted with the automated stratified
groups, the new Stratified CT model improved mortality
prediction when compared to the ILD-GAP model.
When the automated stratified groups were subse-
quently combined with the ILD-GAP model (Stratified
CT-GAP model), mortality prediction was further aug-
mented. Accordingly, automated stratified CALIPER CT
variables have the potential to be used as an alternative
to, or combined with, functional indices to predict out-
come in CTD-ILD patients.
Our observations are particularly relevant given a re-
cent editorial which articulated the need to improve the
identification of distinct disease phenotypes in patients
with rheumatoid arthritis related-ILD to aid risk predic-
tion and diagnosis [30]. Apart from systemic sclerosis,
most studies in the CTD-ILDs have been constrained by
small patient numbers. Accordingly, there is a growing
need to combine patient cohorts across centres to gener-
ate more substantial and inclusive datasets [30]. Al-
though CT evaluation is near ubiquitous in the setting
of known or suspected CTD-ILD, the complexities and
inconsistencies associated with visual CT scoring
demand more robust alternatives for the quantification
of disease patterns and extents.
Computer analysis of CTs in CTD-ILD populations is
an attractive alternative to visual scoring and when com-
bined with the unbiased nature of automated stratifica-
tion, may allow the identification of patient phenotypes
that are visually subliminal. In addition, the strength of
DLco as a predictor of outcome in CTD-ILD may well
be diminished in multicentre cohorts given the variation
associated with DLco measurements across laboratories
[31], further emphasising CT evaluation as a potential
outcome measure in patients with CTD-ILD. In this re-
gard, the ability of automated stratification to substitute
for DLco and FVC measured at a single institution,
without loss of strength in outcome prediction, argues
for consideration of computer-based CT analysis in fu-
ture multicentre CTD-ILD studies.
The improved strength of the Stratified CT-GAP model
over the ILD-GAP model identified in the current study is
largely a consequence of a confounding effect of the normal
range of pulmonary function when PFTs are stratified as
thresholds. The range of normal pulmonary function values
extends across the range of 80–120% of predicted values
based on patient age, gender, race and height. As a result,
in a staging system, if a patient lies close to a lung function
threshold, small differences in predicted normal values will
have a major impact on how the patient is staged, shifting
them above and below thresholds. For example, if a patient
started with a predicted FVC at 120% and lost 35% of pre-
dicted lung function they would remain as GAP stage 1.
However, if the patient started at a predicted FVC of 80%
and lost 35% of predicted FVC, they would fall into GAP
stage 3. Consequently, the normal range has a dramatic
effect on the severe end of the spectrum of disease in de-
termining where someone lies on the GAP scale.
(See figure on previous page.)
Fig. 2 a Kaplan–Meier survival curve demonstrating differences in outcome for patients with connective tissue disease related-interstitial lung disease
separated according to automated stratified groups. Group 1 (blue; mean survival 77.4 ± 2.7 months, n = 15), Group 2 (green; mean survival 66.4 ± 2.7
months, n = 138), Group 3 (yellow; mean survival 47.9 ± 5.2 months, n = 50). Log rank test P < 0.0001. b Kaplan–Meier survival curve demonstrating
differences in outcome for patients with connective tissue disease related-interstitial lung disease separated according to the ILD-GAP model.
Group 1 (blue; mean survival 73.3 ± 2.2 months, n = 28), Group 2 (green; mean survival 74.9 ± 2.7 months, n = 85), Group 3 (yellow; mean survival
53.6 ± 5.1 months, n = 51), Group 4 (magenta; mean survival 20.7 ± 5.5 months, n = 15). Log rank test P < 0.0001. c Kaplan–Meier survival curve
demonstrating differences in outcome for patients with connective tissue disease related-interstitial lung disease separated according to the
Stratified-CT model. Group 1 (blue; mean survival 77.0 ± 3.1 months, n = 13), Group 2 (green; mean survival 77.1 ± 2.3 months, n = 80), Group 3
(yellow; mean survival 57.5 ± 4.1 months, n = 72), Group 4 (magenta; mean survival 17.2 ± 5.6 months, n = 14). Log rank test P < 0.0001
Table 3 Distribution of connective tissue disease-related interstitial lung disease diagnoses across the three groups derived using
automated stratification with percentages in parentheses
RA N = 50 SSc N = 65 SjS N = 10 MCTD N = 16 Myositis N = 23 Overlap N = 36 SLE N = 3
Group 1 4 (8) 5 (8) 0 (0) 2 (13) 1 (4) 3 (8) 0 (0)
Group 2 31 (62) 48 (74) 7 (70) 6 (38) 15 (65) 28 (78) 3 (100)
Group 3 15 (30) 12 (18) 3 (30) 8 (50) 7 (30) 5 (14) 0 (0)
RA rheumatoid arthritis, SSc systemic sclerosis, SjS Sjögrens syndrome, MCTD mixed connective tissue disease, Overlap overlap connective tissue disease, SLE systemic
lupus erythematosus
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A similar limitation of a “normal range” is not present
in morphological CT variables however and CT variables
can therefore serve to modify confounding effects asso-
ciated with clustering around PFT thresholds as identi-
fied in a previous study evaluating a scleroderma staging
system [6]. Goh et al. [6] showed that threshold mea-
sures of CT (Hazard ratio [HR] = 2.5) and PFT (HR = 2.1
for an FVC threshold) variables were significantly
weaker when analysed alone, but improved considerably
when structure and function were combined (HR = 3.5).
Similarly, in the current study, the ILD-GAP model was
a less sensitive predictor of mortality secondary to the
clustering of individuals around PFT thresholds, an ef-
fect that was partially ameliorated following amalgam-
ation of the Stratified CT score to the ILD-GAP model.
The current study is the first of its kind to evaluate
mortality prediction in CTD patients using computer-
based volumetric CT analysis. Several previous studies in
CTD patients analysing CT scans with computer algo-
rithms have utilized interspaced high-resolution CT im-
aging [11, 12], precluding the robust evaluation and
differentiation of patterns such as honeycombing and
emphysema. The remaining computer-based studies
have evaluated the lung according to its simple density
characteristics, deriving metrics of histogram skewness
and kurtosis [32–34]. Such metrics have been shown to
correlate poorly with other markers of disease severity
and with mortality in IPF [15] and are relatively un-
sophisticated compared to modern structural and tex-
tural analytic techniques [27]. Furthermore, only the
studies by Marten et al. [32, 33] evaluated computer
scores against physiological indices whilst the remaining
studies compared computer-based scores with visual CT
scoring. No studies to date have evaluated computer
scores against mortality in patients with CTD.
CALIPER has advantages over most quantitative tools
by virtue of its volumetric structural and textural analysis
of the lung, which, for example, enables low attenuation
areas of the lung to be distinguished as representing either
Fig. 3 a Receiver operating characteristic (ROC) curves demonstrating
sensitivity and specificity for overall mortality prediction using three
models: ILD-GAP model (Blue; AUROCC= 0.72, P < 0.0001, CI 0.64–0.80),
Stratified-CT Model (Green; AUROCC= 0.74, P < 0.0001, CI 0.66–0.82),
Stratified CT-GAP model (Yellow; AUROCC = 0.74, P < 0.0001, CI
0.66–0.82). b ROC curves demonstrating sensitivity and specificity
for prediction of death within a year from the patients initial CT
scan using three models: ILD-GAP model (Blue; AUROCC = 0.87,
P < 0.0001, CI 0.80–0.95), Stratified-CT Model (Green; AUROCC = 0.88,
P < 0.0001, CI 0.81–0.95), Stratified CT-GAP model (Yellow; AUROCC=
0.89, P < 0.0001, CI 0.82–0.97). c ROC curves demonstrating sensitivity
and specificity for prediction of death within 2 years from the patients
initial CT scan using three models: ILD-GAP model (Blue; AUROCC=
0.86, P < 0.0001, CI 0.80–0.93), Stratified-CT Model (Green; AUROCC =
0.83, P < 0.0001, CI 0.75–0.90), and Stratified CT-GAP model (Yellow;
AUROCC = 0.88, P < 0.0001, CI 0.82–0.95)
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honeycombing or emphysema [27]. Similarly, volumetric
analysis allows quantitation of features that cannot be re-
solved visually, such as the percentage of the lung volume
composed of vessels [25]. A glyph distils CALIPERs quan-
titative data into a format that is easily deciphered by the
non-specialist in a busy clinic setting, which may have
crossover utility for both rheumatologists and pulmonolo-
gists in the evaluation of patients with CTD-ILD. Whilst
the glyph presentations are a by-product of CALIPER ana-
lysis we do not wish to give undue prominence to them in
the current study however, since it is based on population
characteristics rather than individual patient/glyph ap-
pearances. Interrogating an individual glyph, which simpli-
fies complex spatial patterns of disease morphology and
extent, is an inferior exercise when compared to the mod-
elling analyses conducted in the current study. To derive
absolute conclusions about an individual’s likely outcome
based solely on a glyph would be misleading.
There are very few large-scale studies that have evalu-
ated the ability of CT variables to predict mortality
across all CTD subtypes. A study by Walsh et al. [7]
evaluated CTs and pulmonary function indices in 168
patients with various CTDs and found that traction
bronchiectasis severity and honeycombing extent scored
visually along with DLco were independently predictive
of mortality. In the present study, across all CTD-ILD
patients, when visually scored CT parameters were ana-
lysed alone, visual honeycombing and traction bronchi-
ectasis severity scores were also independently predictive
of mortality. However, when combined with CALIPER
CT variables and PFTs, however, visual honeycombing
and traction bronchiectasis scores did not retain prog-
nostic significance.
The association between pulmonary hypertension and
connective tissue diseases has long been recognised [35],
and supervening pulmonary hypertension is associated
with a poor outcome across the range of CTDs [36–38].
It would therefore be logical to assume that the mortal-
ity signal associated with PVV reflected a new imaging
marker of pulmonary hypertension. However, as with
our observations in patients with idiopathic pulmonary
fibrosis [25, 39], we identified only weak linkages be-
tween PVV and both RVSP and Kco. Indeed, Kco and
PVV were independently predictive of mortality across
the range of CTD patients. The findings suggest that the
PVV signal does not primarily reflect the severity of pul-
monary hypertension, or indeed act as a key marker of
damage to the vascular compartment of the lung. The
counter-intuitive relationship between PVV and the extent
of ILD identified on CT may, as previously postulated, be
explained by local increased vascular pressures within fi-
brotic regions of the lung that result in blood diversion
to spared lung regions. As fibrosis worsens and vessel
size and number (above a size threshold recognised by
CALIPER) increase in non-fibrotic regions of the lung, the
accompanying increase in CALIPER PVV may effectively
act as a surrogate marker of ILD extent [39].
The superiority of PVV in predicting mortality over
CALIPER and visually scored total ILD extents may re-
late to the specific pathophysiologic changes that de-
velop in the lung secondary to fibrosis. As fibrosis
worsens, the lung contracts with the result that the ex-
tent of fibrosis, when measured volumetrically or
expressed as a proportion of the total lung volume may,
in fact, decrease. Consequently, in a patient with more
severe disease, a volumetric CT score of fibrosis extent
underestimates fibrosis severity. PVV avoids such a pit-
fall, as it is a parameter that increases in line with fibro-
sis extent. Evaluation of PVV as a prognostic marker in
the fibrosing lung diseases remains in its infancy; how-
ever, results from the current study argue for further de-
tailed study of the variable in other fibrosing lung
diseases as well as evaluation of PVV as a marker of de-
terioration on serial CT evaluation.
There are some limitations to this retrospective study.
Firstly, the individual CTD-ILD diagnoses making up
the cohort were not evenly distributed, for example,
there were large numbers of RA-ILD and systemic
sclerosis-ILD patients but very few cases of SLE. In miti-
gation, however, given that the study population repre-
sented a consecutive cohort of new clinic presentations,
the case mix arguably represents a real-world caseload.
Secondly, there were only 14 patients in automated
stratified group 1, limiting the strength of statistical rela-
tionships between groups. A consequence was that the
remaining patients were split into two groups generating
dichotomous good and bad outcome groups. Since most
management decisions are binary with regard to giving
or withholding medication, a two-group model is usually
preferable to a multiple group model where managing
patients in intermediate outcome groups is problematic.
It could also be argued that some patients with an ap-
parently good outcome may turn out to have a delayed
poor outcome once treatment benefits have dissipated.
Such a reservation is common to a great many studies,
and yet primarily evaluating all patients at presentation
does, at least, provide a satisfactory spread of disease
severity, including some patients with earlier disease
and others with more advanced disease. There are limi-
tations associated with making exact prognostic separa-
tions based on baseline evaluation and conclusions
reached at a single point in time should retain some
flexibility to enable modification by observed changes
in subsequent disease behaviour. Finally, an external
validation cohort would ideally have been used to con-
firm our findings; however, the scarcity of large, well
characterised fibrosing lung disease cohorts remains a
recognised constraint.
Jacob et al. BMC Medicine  (2016) 14:190 Page 11 of 13
Conclusions
In conclusion, we have demonstrated that, in a large
mixed population of CTD-ILD patients, CALIPER pul-
monary vessel volume was the CT variable that best
predicted mortality and may be a new prognostic index.
When automated stratified CALIPER variables were
substituted for the functional indices in the ILD-GAP
index, mortality prediction was strengthened. Com-
puter analysis and automated stratification of CTs may
therefore represent a viable alternative to visual CT
scoring and evaluation of functional indices in patients
with CTD-ILD, and demonstrates added value when
combined with outcome prediction models such as the
ILD-GAP model.
Additional file
Additional file 1 Table S1. Lobar visual scores were adjusted using
scintigraphic and gas dilution measures of the physiological contribution
of each lobe to the total lung volume in health (top row). The figure was
divided by the proportion of each lung representing a lobe (16.7%), or in
the case of the left upper lobe, which included the lingula, two lobes
(33.3%). Table S2. Single determination standard deviation values of
visual CT scores for connective tissue disease-related interstitial lung disease
cases. Table S3. Patient age, gender, smoking status and measures of
pulmonary function indices, CALIPER and visually scored CT parameters
and echocardiography data for the four groups of the ILD-GAP index.
Data represent mean values with standard deviations. CTD, connective
tissue disease; FEV1, forced expiratory volume in one second; FVC,
forced vital capacity; DLco, diffusing capacity for carbon monoxide;
Kco, carbon monoxide transfer coefficient; TLC, total lung capacity; CPI,
composite physiologic index; ILD, interstitial lung disease; GGO, ground
glass opacity; PVV, pulmonary vessel volume; TxBx, traction bronchiectasis;
PA, pulmonary artery; AAo, ascending aorta; RVSP, right ventricular systolic
pressure. Table S4. P values demonstrating differences between automated
stratified groups calculated using one-way ANOVA with Bonferroni
correction for continuous variables and t-test with Bonferroni correction
for categorical variables. ILD, interstitial lung disease; PA, pulmonary
artery; Ao, ascending aorta; HC, honeycombing; DLco, diffusing capacity
for carbon monoxide; Kco, carbon monoxide transfer coefficient; CPI,
composite physiologic index; RVSP, right ventricular systolic pressure.
* not significant. Figure S1. CONSORT diagram illustrating the selection
of patients for the final study population. ILD, interstitial lung disease; CTD,
connective tissue disease; IPAF, interstitial pneumonia with autoimmune
features; LCH, Langerhans cell histiocytosis; LAM, lymphangioleiomyomatosis;
CT, computed tomography. (DOCX 67 kb)
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